Afya surges as direct US listing bypasses typical Brazil ADR hurdles

A quiet revolution in how foreign investors access Brazilian healthcare is playing out on Wall Street. Shares of Afya Limited, Brazil's largest medical education group, surged 4.24% to close at $14.75, highlighting a unique corporate structure that sets it apart from almost all of its domestic peers.

Unlike traditional Brazilian giants such as state-run oil firm Petrobras or mining powerhouse Vale, which trade in New York via American Depositary Receipts (ADRs), Afya bypassed the ADR system entirely. Incorporated in the Cayman Islands with its primary operational headquarters in Belo Horizonte, Brazil, Afya launched its initial public offering directly on the Nasdaq. For international retail investors, this direct-listing model eliminates the complex custody fees, conversion math, and liquidity bottlenecks often associated with ADRs, allowing them to trade the stock as easily as any domestic US tech firm.

This structural advantage comes at a pivotal moment for the company. On September 23, 2026, Afya signed a definitive agreement to merge with rival Brazilian higher-education group Yduqs. The transaction, which is currently awaiting antitrust clearance from Brazil’s Administrative Council for Economic Defense (CADE), will create an education titan with a combined revenue of approximately $2.3 billion. Under the terms of the deal, Afya will merge into Yduqs, with the combined entity surviving on Brazil's B3 exchange under the Novo Mercado segment.

The merger represents a massive consolidation in Brazil’s highly lucrative private medical education sector. Private medical schools in Brazil are heavily regulated by the Ministry of Education, which strictly controls the number of student seats authorized nationwide to maintain training standards. Just days before the merger announcement, on September 18, 2026, Afya secured regulatory approval to add 17 medical seats at its campus in Cruzeiro do Sul, in the remote northern state of Acre, bringing its total network capacity to 3,785 seats. This tight regulatory cap on medical seats makes existing licenses incredibly valuable, driving intense competition and corporate tie-ups.

For foreign observers, the transaction also signals a shift in how they will access this market. Because the surviving combined company will list its common shares solely on Brazil's local B3 exchange, Afya’s Class A common shares will eventually be delisted from the Nasdaq once the merger is finalized. US retail investors who do not qualify as institutional buyers will eventually receive net cash proceeds from a post-closing sale process rather than direct shares in the new local entity, marking the final chapters of one of the few direct Brazilian listings on Wall Street.

What it touches

The ongoing merger and regulatory approvals directly impact Afya Limited (NASDAQ: AFYA) and its merger partner Yduqs Participações S.A. (B3: YDUQ3). The consolidation reshapes the broader private education sector in Brazil, affecting competitors like Cogna Educação and Ser Educacional as they navigate a market increasingly dominated by a single massive player.